Angela L Bosma1, Linde E M de Wijs2, Michel H Hof3, Beau R van Nieuwenhuizen4, Louise A A Gerbens4, Maritza A Middelkamp-Hup4, DirkJan Hijnen2, Phyllis I Spuls4. 1. Department of Dermatology, Amsterdam Public Health, Immunity and Infections, Amsterdam University Medical Centers, location AMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: a.l.bosma@amsterdamumc.nl. 2. Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands. 3. Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam University Medical Centers, location AMC, University of Amsterdam, Amsterdam, the Netherlands. 4. Department of Dermatology, Amsterdam Public Health, Immunity and Infections, Amsterdam University Medical Centers, location AMC, University of Amsterdam, Amsterdam, the Netherlands.
Abstract
BACKGROUND: Evidence on long-term dupilumab treatment for atopic dermatitis in daily practice is lacking. OBJECTIVE: To investigate patient characteristics, treatment aspects, effectiveness, and safety of up to 84 weeks of dupilumab treatment. METHODS: An observational prospective cohort study was conducted of patients with atopic dermatitis starting dupilumab in routine clinical care. RESULTS: Of the 221 included patients, 103 used systemic therapy at baseline. At 84 weeks, we found a change of -15.2 (SE, 1.7) for the Eczema Area and Severity Index, -16.9 (SE, 1.4) for the Patient-Oriented Eczema Measure, and -17.2 (SE, 1.6) for the Dermatology Life Quality Index. We found a trend for improvement over time for the Investigator Global Assessment and Numerical Rating Scale for pruritus. Severe (n = 79) including serious (n = 11) adverse events were observed in 69 patients. Eye complaints were most frequently reported (n = 46). Twenty-one patients adjusted the regular dosing schedule, and 14 patients discontinued treatment, mainly due to ineffectiveness (n = 7). LIMITATIONS: Only adverse events of severe and serious nature were registered for feasibility reasons. CONCLUSION: Daily practice dupilumab treatment of up to 84 weeks is generally well-tolerated, apart from the reporting of eye complaints. It can be considered a long-term effective treatment for atopic dermatitis in combination with topical and initial concomitant systemic treatment, showing a sustained improvement of signs, symptoms, and quality of life.
BACKGROUND: Evidence on long-term dupilumab treatment for atopic dermatitis in daily practice is lacking. OBJECTIVE: To investigate patient characteristics, treatment aspects, effectiveness, and safety of up to 84 weeks of dupilumab treatment. METHODS: An observational prospective cohort study was conducted of patients with atopic dermatitis starting dupilumab in routine clinical care. RESULTS: Of the 221 included patients, 103 used systemic therapy at baseline. At 84 weeks, we found a change of -15.2 (SE, 1.7) for the Eczema Area and Severity Index, -16.9 (SE, 1.4) for the Patient-Oriented Eczema Measure, and -17.2 (SE, 1.6) for the Dermatology Life Quality Index. We found a trend for improvement over time for the Investigator Global Assessment and Numerical Rating Scale for pruritus. Severe (n = 79) including serious (n = 11) adverse events were observed in 69 patients. Eye complaints were most frequently reported (n = 46). Twenty-one patients adjusted the regular dosing schedule, and 14 patients discontinued treatment, mainly due to ineffectiveness (n = 7). LIMITATIONS: Only adverse events of severe and serious nature were registered for feasibility reasons. CONCLUSION: Daily practice dupilumab treatment of up to 84 weeks is generally well-tolerated, apart from the reporting of eye complaints. It can be considered a long-term effective treatment for atopic dermatitis in combination with topical and initial concomitant systemic treatment, showing a sustained improvement of signs, symptoms, and quality of life.
Authors: Lieneke F M Ariëns; Daphne S Bakker; Lotte S Spekhorst; Jorien Van der Schaft; Judith L Thijs; Inge Haeck; Annebeth E Flinterman; Marijke Kamsteeg; Marie L A Schuttelaar; Marjolein S De Bruin-Weller Journal: Acta Derm Venereol Date: 2021-10-19 Impact factor: 3.875
Authors: Jerry Bagel; Tien Q Nguyen; Hermenio Lima; Neal Jain; David M Pariser; Sylvia Hsu; Gil Yosipovitch; Haixin Zhang; Jingdong Chao; Shikha Bansal; Zhen Chen; Daniel Richman; Andrew Korotzer; Marius Ardeleanu Journal: Dermatol Ther (Heidelb) Date: 2022-05-20
Authors: Lawrence F Eichenfield; April Armstrong; Emma Guttman-Yassky; Peter A Lio; Chi-Chang Chen; Dionne M Hines; Catherine B McGuiness; Sohini Ganguli; Dimittri Delevry; Debra Sierka; Usha G Mallya Journal: Dermatol Ther (Heidelb) Date: 2022-05-11
Authors: Aaron M Drucker; Megan Lam; Carsten Flohr; Jacob P Thyssen; Kenji Kabashima; Robert Bissonnette; Ncoza C Dlova; Valeria Aoki; Max Chen; Joshua Yu; Jie Wei Zhu; Robert Micieli; Audrey Nosbaum Journal: Dermatitis Date: 2022-03-15 Impact factor: 4.867
Authors: Jonathan I Silverberg; H Chih-Ho Hong; Jacob P Thyssen; Brian M Calimlim; Avani Joshi; Henrique D Teixeira; Eric B Collins; Marjorie M Crowell; Scott J Johnson; April W Armstrong Journal: Dermatol Ther (Heidelb) Date: 2022-04-18